Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03954171

Platino-resistance in Ovarian Cancer

Prospective, monocentric study aiming to identify factors involved in platinum based-chemotherapy resistance in patients with epithelial ovarian cancer (all stages).

Patients will receive treatment (platinum based-chemotherapy) according to the standard practices.

A prospective database and an associated biological collection will be performed during 5 years:

* For each patient: clinical, biological, epidemiological and therapeutic treatment data will be collected during the standard therapeutic care. * Biological samples (blood samples, tumor biopsy specimens and ascites samples) will be collected for all patients. These samples will be collected at the same time as those taken in standard practice (no additional biopsy will be performed for the study).

Study participation of each patient will be 5 years.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Epithelial Ovarian Cancer Adnexal Diseases Carcinoma Carcinoma, Ovarian Epithelial Endocrine Gland Neoplasms Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Gonadal Disorders Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Ovarian Diseases Ovarian Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Institut Universitaire du Cancer de Toulouse - Oncopole

Toulouse, France

Location status: Recruiting

Location contact

Gwenaël FERRON

CONTACT

[email protected]

05 31 15 53 55

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years old
  • Epithelial ovarian cancer at initial diagnosis (all stages)
  • Curative treatment (exeresis surgery) not yet initiated excepted neo-adjuvant treatment
  • Indication of platinum based-chemotherapy
  • Patient affiliated to the french social security system
  • Patient must provide written informed consent prior to inclusion in the study and any study-specific procedure

Exclusion criteria

  • Non-epithelial ovarian tumor, borderline ovarian tumor
  • Patient with recurrent disease
  • Exploratory surgery not performed at the "Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT-O)"
  • Pregnant or breastfeeding women
  • Any psychological, familial, geographical or sociological condition potentially preventing the medical follow-up and/or study procedures
  • Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice)

Treatment and study plan

Patients treated with platinum based-chemotherapy

Other

Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice):

  • before treatment initiation (blood sample),
  • during hospitalisation for surgery (blood sample),
  • during follow-up consultations (blood sample).

If tumor biopsy and/or ascites sampling are performed during the standard care, a sample will be collected for the study.

Primary outcomes

  1. The rate of patients alive without progression

    Time frame: 5 years for each patient

Secondary outcomes

  1. The time to onset of platinum based-chemotherapy resistance

    Time frame: 5 years for each patient

Study contacts

Contact information is provided by the study sponsor or research team.

Gwenaël FERRON

CONTACT

[email protected]

05 31 15 53 55

Sponsors and collaborators

Lead sponsor

Institut Claudius Regaud

Other

Registry information

Acronym: PlatinOv

Important dates

Study start
2020
Primary completion
2033
Study completion
2033
First posted
May 17, 2019
Registry last updated
Nov 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.